MODERN Study Stopped: An NRTI-Sparing, Two-Drug Initial Regimen Disappoints Again

Another NRTI-sparing study falls short, leading Dr. Paul Sax in his HIV and ID Observations blog to question why two-drug regimens have been so disappointing.

A trial comparing maraviroc with tenofovir/FTC (MODERN) yielded disappointing results (72% suppression rates at 48 weeks) and has become one of seven recent NRTI-sparing studies to fall short. In his HIV and ID Observations blog, Dr. Paul Sax wonders why two-drug regimens have been so discouraging and recommends that NRTI-sparing therapies be used as initial treatment only in highly select circumstances.

MODERN Study Stopped: An NRTI-Sparing, Two-Drug Initial Regimen Disappoints Again

Topics